Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in...

Descripción completa

Detalles Bibliográficos
Autores principales: Contag, Caitlin A., Mische, Leah, Fong, Isabel, Karan, Abraar, Vaidya, Akanksha, McCormick, David W., Bower, William, Hacker, Jill K., Johnson, Kelly, SanJuan, Perla, Crebbin, Linda, Temmins, Caroline, Sahni, Harleen, Bogler, Yael, Cooper, Joseph D., Narasimhan, Supriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683816/
https://www.ncbi.nlm.nih.gov/pubmed/37856215
http://dx.doi.org/10.3201/eid2912.230849
_version_ 1785151272477786112
author Contag, Caitlin A.
Mische, Leah
Fong, Isabel
Karan, Abraar
Vaidya, Akanksha
McCormick, David W.
Bower, William
Hacker, Jill K.
Johnson, Kelly
SanJuan, Perla
Crebbin, Linda
Temmins, Caroline
Sahni, Harleen
Bogler, Yael
Cooper, Joseph D.
Narasimhan, Supriya
author_facet Contag, Caitlin A.
Mische, Leah
Fong, Isabel
Karan, Abraar
Vaidya, Akanksha
McCormick, David W.
Bower, William
Hacker, Jill K.
Johnson, Kelly
SanJuan, Perla
Crebbin, Linda
Temmins, Caroline
Sahni, Harleen
Bogler, Yael
Cooper, Joseph D.
Narasimhan, Supriya
author_sort Contag, Caitlin A.
collection PubMed
description Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in California, USA, that had suspected tecovirimat resistance.
format Online
Article
Text
id pubmed-10683816
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-106838162023-12-01 Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022 Contag, Caitlin A. Mische, Leah Fong, Isabel Karan, Abraar Vaidya, Akanksha McCormick, David W. Bower, William Hacker, Jill K. Johnson, Kelly SanJuan, Perla Crebbin, Linda Temmins, Caroline Sahni, Harleen Bogler, Yael Cooper, Joseph D. Narasimhan, Supriya Emerg Infect Dis Dispatch Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in California, USA, that had suspected tecovirimat resistance. Centers for Disease Control and Prevention 2023-12 /pmc/articles/PMC10683816/ /pubmed/37856215 http://dx.doi.org/10.3201/eid2912.230849 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Contag, Caitlin A.
Mische, Leah
Fong, Isabel
Karan, Abraar
Vaidya, Akanksha
McCormick, David W.
Bower, William
Hacker, Jill K.
Johnson, Kelly
SanJuan, Perla
Crebbin, Linda
Temmins, Caroline
Sahni, Harleen
Bogler, Yael
Cooper, Joseph D.
Narasimhan, Supriya
Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
title Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
title_full Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
title_fullStr Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
title_full_unstemmed Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
title_short Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
title_sort treatment of mpox with suspected tecovirimat resistance in immunocompromised patient, united states, 2022
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683816/
https://www.ncbi.nlm.nih.gov/pubmed/37856215
http://dx.doi.org/10.3201/eid2912.230849
work_keys_str_mv AT contagcaitlina treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT mischeleah treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT fongisabel treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT karanabraar treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT vaidyaakanksha treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT mccormickdavidw treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT bowerwilliam treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT hackerjillk treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT johnsonkelly treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT sanjuanperla treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT crebbinlinda treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT temminscaroline treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT sahniharleen treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT bogleryael treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT cooperjosephd treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022
AT narasimhansupriya treatmentofmpoxwithsuspectedtecovirimatresistanceinimmunocompromisedpatientunitedstates2022

Ejemplares similares